SERCA2 regulates Piezo1 channel activation and contributes to the cardiac function and baroreflex in mice

  • Acta Pharmacol Sin. 2025 Jul 9. doi: 10.1038/s41401-025-01610-x.
Jia-Xin Zhao  1 Yin-Zhi Xu  1 Hui-Xiao Fu  1 Jia-Qun Li  1 Mao Yue  1 Zhao-Yuan Xu  1 Xue-Lian Li  1 Chang-Peng Cui  2 Bai-Yan Li  3
Affiliations
  • 1. State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State Key Laboratory-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • 2. State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State Key Laboratory-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China. [email protected].
  • 3. State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State Key Laboratory-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China. [email protected].
Abstract

Piezo1 channels play important roles in physiological processes such as tactile sensation, blood pressure (BP) control, cardiac development, inflammatory responses as well as in disease processes. Sarco-endoplasmic reticulum CA2+-transporting ATPase (SERCA) is the only active protein in the SR that orchestrates calcium homeostasis by translocation of CA2+ from the cytoplasm to the sarcoplasmic reticulum. It has been shown that SERCA2 inhibits Piezo1 function in mammals by directly acting on the Piezo1 mechano-transduction module of mechanosensitive ion channels. In this study, we investigated whether SERCA2 regulates Piezo1 activation indirectly by modulating CA2+ homeostasis. We showed that treatment with a Piezo1 agonist Yoda1 (5 µM) markedly increased the viability and ATP synthesis of primary cardiomyocytes as well as intracellular CA2+ content through activation of Piezo1, and upregulated the expression of Piezo1 and SERCA2 in the cardiomyocytes. However, si-Piezo1 transfection resulted in downregulation of SERCA2 expression with opposite effects on viability and ATP synthesis and intracellular CA2+ content that could not be reversed by application of Yoda1. Interestingly, application of a SERCA2 channel inhibitor paxilline (Pax, 10 µM) reversed the inhibitory effect of si-Piezo1 transfection on cardiomyocyte function. Using patch clamping and CA2+ transient analyses in cardiomyocytes, we demonstrated that application of Pax inhibited Yoda1-mediated CA2+ currents and APD50, confirming that Piezo1 activation by Yoda1 was significantly inhibited by Pax. Furthermore, application of Yoda1 was able to reverse si-SERCA2 transfection-induced impairment of myocardial function. Microinjection of Yoda1 and Pax into nodose ganglion (NG) in HFD-HTN model rats also demonstrated that the effect of Yoda1 was inhibited in the presence of Pax, thus confirming that Pax inhibited intracellular CA2+ recycling by SERCA2. These results demonstrate for the first time that the application of Pax inhibits the recycling of intracellular CA2+ by SERCA2 and reverses the reduction in cardiomyocyte function caused by downregulation of Piezo1 expression.

Keywords
Piezo1; SERCA2; Yoda1; cardiomyocyte; intracellular Ca2+ recycling; paxilline.
Products